TGFB1 and cancer: Vigil (also termed gemogenovatucel-T, developed by Gradalis) is an autologous cancer vaccine that expresses granulocyte-macrophage colony-stimulating factor and decreases the expression of furin and its downstream TGF-β1 and TGF-β2 (89).